Epic Sciences of San Diego closed a $40 million Series D financing led by Hong Kong’s Hermed Capital. Epic is developing a portfolio of blood-based tests that predict drug response in cancer. Its most advanced product, the OncotypeDx AR-V7 Nucleus Detect test, helps physicians decide whether taxane chemotherapy or targeted therapies is the better treatment for metastatic castration-resistant prostate cancer. Hermed intends to help Epic bring its product(s) to China.
China Med Device, LLC, specializing in providing turn-key solutions for medtech companies’ entry into China. We accelerate medtech and medical device companies’ growth with needed capital injection, funding partnership, merger and acquisition consulting. If you have any feedback on this post or would like to know more of our services, please email us at info@ChinaMedDevice.com or visit us at www.ChinaMedDevice.com.